The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First prospective multicenter Italian study on the impact of the 21-Gene Recurrence Score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients.
 
Maria Vittoria Dieci
Consulting or Advisory Role - Celgene; Genomic Health; Ipsen; Novartis
Research Funding - Genomic Health (Inst)
Travel, Accommodations, Expenses - Celgene; Myriad Genetics
 
Valentina Guarneri
Consulting or Advisory Role - AstraZeneca; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene
 
Tommaso Giarratano
No Relationships to Disclose
 
Marta Mion
Consulting or Advisory Role - Roche
 
Giampaolo Tortora
No Relationships to Disclose
 
Paolo Morandi
Travel, Accommodations, Expenses - Roche
 
Stefania Gori
No Relationships to Disclose
 
Laura Merlini
Consulting or Advisory Role - AstraZeneca; Italfarmaco; Novartis
 
Cristina Oliani
No Relationships to Disclose
 
Felice Pasini
No Relationships to Disclose
 
Giorgio Bonciarelli
No Relationships to Disclose
 
Gaia Griguolo
No Relationships to Disclose
 
Enrico Orvieto
No Relationships to Disclose
 
Paola Del Bianco
No Relationships to Disclose
 
Gian Luca De Salvo
No Relationships to Disclose
 
Pier Franco Conte
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Roche/Genentech
Research Funding - Merck Serono; Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis